Search Result
Results for "
Racemic
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
31
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-19966
-
|
|
Kinesin
Apoptosis
|
Cancer
|
|
K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC50 of 1.3 μM.
|
-
-
- HY-14605BS
-
|
AGN1135-13C3; TVP1012-13C3 Racemic
|
Isotope-Labeled Compounds
Monoamine Oxidase
|
Neurological Disease
|
|
Rasagiline- 13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor . Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-100869B
-
|
|
WDR5
|
Cancer
|
|
MM-589 (racemic mixture) TFA, is a racemic mixture of MM-589 TFA (HY-100869A). MM-589 TFA is a potent inhibitor of WD repeat domain 5 (WDR5) and mixed lineage leukemia (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC50 of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC50 of 12.7 nM .
|
-
-
- HY-145263A
-
-
-
- HY-107501
-
|
(Rac)-1-Oleoyl-sn-glycero-3-phosphate sodium; (Rac)-1-Oleoyl-LPA sodium
|
LPL Receptor
|
Neurological Disease
|
|
(Rac)-1-Oleoyl lysophosphatidic acid ((Rac)-1-Oleoyl-sn-glycero-3-phosphate) sodium is the racemic isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614) .
|
-
-
- HY-16023B
-
|
EM-343; (Rac)-EM-652
|
Estrogen Receptor/ERR
|
Cancer
|
|
(Rac)-Acolbifene (EM-343; (Rac)-EM-652) is the racemic form of EM652 (estrogen receptor?antagonist), has anti-estrogenic and estrogenic activities. (Rac)-Acolbifene (EM-343; (Rac)-EM-652) contains a piperidine ring, shows good pharmacological profile,relative binding affinity (RBA)=380 .
|
-
-
- HY-U00356
-
-
-
- HY-150649
-
|
|
17β-HSD
|
Cancer
|
|
S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance .
|
-
-
- HY-70028
-
|
|
MDM-2/p53
E1/E2/E3 Enzyme
|
Cancer
|
|
p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.
|
-
-
- HY-110406A
-
|
13-Hydroperoxylinoleic acid; Linoleic acid 13-hydroperoxide
|
Endogenous Metabolite
|
Others
|
|
(±)13-HpODE (13-hydroperoxylinoleic acid) is a racemic mixture of hydroperoxides, which is produced by the oxidation of linoleic acid by lipoxygenase .
|
-
-
- HY-120723
-
-
-
- HY-120109
-
|
|
Endogenous Metabolite
|
Cancer
|
|
13-HODE methyl ester, a racemic mixture of 13(R)-HODE methyl ester and 13(S)-HODE methyl ester, is a 15-lipoxygenase metabolite of Linoleic acid .
|
-
-
- HY-118590A
-
|
|
Topoisomerase
|
Cancer
|
|
ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193 (HY-118590). ICRF-193 is an TopoII inhibitor. ICRF-196 can be used for the research of cancer .
|
-
-
- HY-118590
-
|
|
Topoisomerase
|
Cancer
|
|
ICRF-193 is an TopoII inhibitor. (S,S)- and (R,R)-isomers ICRF-193 make up an racemic mixture, ICRF-196 (HY-118590A). ICRF-196 can be used for the research of cancer .
|
-
-
- HY-120408
-
|
Atroscine
|
Adrenergic Receptor
|
Neurological Disease
|
|
(±)-Scopolamine (Atroscine) is the racemic modification of Scopolamine. (±)-Scopolamine inhibits α-adrenergic receptor activity. (±)-Scopolamine has Ki values of 33 μM and 7.25 nM for α1-adrenerg receptor and muscarinic cholinergic receptor, respectively .
|
-
-
- HY-102094
-
|
|
mGluR
|
Neurological Disease
|
|
(E/Z)-SIB-1893 is a racemic compound of (E)-SIB-1893 and (Z)-SIB-1893 isomers. (E)-SIB-1893 is a selective non-competitive metabotropic glutamate subtype 5 receptor (mGluR5) antagonist .
|
-
-
- HY-10011B
-
|
|
CXCR
|
Inflammation/Immunology
Endocrinology
|
|
(Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active CXCR2 and CXCR1 antagonist with IC50 values of 1.3 nM and 7.3 nM and Ki values of 1 nM and 3 nM, respectively .
|
-
-
- HY-130319A
-
|
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
|
9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
|
-
-
- HY-113972A
-
|
|
Drug Isomer
|
Inflammation/Immunology
|
|
(E/Z)-Methyl mycophenolate is a racemic compound of (Z)-Methyl mycophenolate and (E)-Methyl mycophenolate isomers. Methyl mycophenolate is a methyl ester of mycophenolic acid. Methyl mycophenolate can be used to synthesize mycophenolic acid β-D-glucuronide and phenolic glycosides .
|
-
-
- HY-127009
-
|
Levofolinic acid; Levofolene
|
Endogenous Metabolite
|
Cancer
|
|
Levoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer .
|
-
-
- HY-116663
-
|
(±)20-HDoHE
|
Endogenous Metabolite
|
Neurological Disease
|
|
(±)20-HDHA ((±)20-HDoHE) is a racemic mixture and is an autoxidation product of Docosahexaenoic acid (DHA). (±)20-HDHA is also formed by peroxidation process in human platelets and rat brain homogenate .
|
-
-
- HY-107370AS
-
|
(Rac)-Tomoxetine d7 hydrochloride; (Rac)-LY 139603 d7
|
Serotonin Transporter
Sodium Channel
Isotope-Labeled Compounds
|
Neurological Disease
|
|
(Rac)-Atomoxetine-d7 (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .
|
-
-
- HY-W010712
-
|
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-His (Trt)-OH is a histidine derivative. Fmoc-His(Trt)-OH has trityl (Trt) group to protect the side-chain of His. Fmoc-His(Trt)-OH has Fmoc group to protect -αNH2. Fmoc-His(Trt)-OH can be used for solid phase synthesis of peptides, providing protection against racemization and by-product formation .
|
-
-
- HY-118091
-
|
|
5 alpha Reductase
|
Endocrinology
|
|
LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1 .
|
-
-
- HY-B0203B
-
|
(Rac)-R 065824
|
Adrenergic Receptor
NADPH Oxidase
|
Cardiovascular Disease
|
|
(Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity .
|
-
-
- HY-101526R
-
|
GENZ-882706 racemate
|
c-Fms
|
Others
|
|
GENZ-882706(Raceme) is the racemate of GENZ-882706. GENZ-882706(Raceme) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-B0203BS2
-
|
(Rac)-R 065824-d2,15N
|
NADPH Oxidase
Adrenergic Receptor
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
(Rac)-Nebivolol-d2, 15N is 15N and deuterated labeled (Rac)-Nebivolol (HY-B0203B). (Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity .
|
-
-
- HY-131445A
-
|
|
Orphan Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
SS-RJW100 is a enantiomer of RJW100, which is a racemic agonist of nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1). SS-RJW100 promotes recruitment of coregulator protein fragments in vitro, recruits the transcriptional intermediary factor 2 (Tif2) coactivator to LRH-1. SS-RJW100 diminishes LRH-1 allosteric activation networks, shows poor thermal stability .
|
-
-
- HY-172008
-
-
-
- HY-14735
-
|
XP 19986
|
GABA Receptor
|
Neurological Disease
|
|
Arbaclofen placarbil is a novel transported proagent of the active R-isomer of baclofen. Baclofen is a racemic GABAB receptor agonist
|
-
-
- HY-B2236
-
|
(±)-2,6-Diaminocaproic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins .
|
-
-
- HY-134818
-
-
-
- HY-B2236A
-
|
(±)-2,6-Diaminocaproic acid monohydrate
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
DL-Lysine monohydrate is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins .
|
-
-
- HY-B0399A
-
|
(±)-Carnitin
|
Mitochondrial Metabolism
|
Metabolic Disease
|
|
DL-Carnitine is a racemic mixture of L-Carnitine and D-Carnitine, regulates fatty acid transport in mitochondria, elevates serum carnitine fractions.
|
-
-
- HY-W017442
-
|
|
Endogenous Metabolite
|
Others
|
|
DL-Asparagine is a racemic melange of the Aparagine L and D-enantiomers. DL-Asparagine has been used in growth-media for bacteria-growth .
|
-
-
- HY-106601
-
|
LY-150720
|
Opioid Receptor
|
Neurological Disease
|
|
Picenadol (LY-150720) is a racemic opioid that can be used in combination with other opioids. Picenadol has anticholinergic activity .
|
-
-
- HY-114514
-
-
-
- HY-N3422A
-
|
|
Drug Isomer
|
Cancer
|
|
(rac)-Khellactone is the racemic form of Khellactone. (rac)-Khellactone is a type of coumarin, and its derivatives are expected to be used in the research of the anti-cancer field .
|
-
-
- HY-120658
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
(Rac)-LY193239 is a racemic modification of LY193239 (HY-120658A). LY193239 is a higher-lactam pyrazolidinone antibacterial agent .
|
-
-
- HY-12993A
-
|
A-60444 racemate
|
RSV
|
Others
|
|
RSV604 (A-60444) racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.
|
-
-
- HY-18733
-
-
-
- HY-172009
-
|
|
Drug Isomer
|
Others
|
|
8-Amino-7-oxononanoic acid hydrochloride is a racemic mixture of 8(R)-KAPA and the vitamer of biotin 8(S)-KAPA.
|
-
-
- HY-W127386
-
|
3-Dodecyloxypropane-1,2-diol
|
Biochemical Assay Reagents
|
Others
|
|
1-O-Dodecyl-rac-glycerol is a class of organic compounds belonging to the class of racemic glycerol derivatives. It consists of a dodecyl chain attached to the sn-1 position of the racemic glycerol molecule. 1-O-Dodecyl-rac-glycerol has various applications in the pharmaceutical industry, especially as an intermediate in the synthesis of lipid drug delivery systems and membranes. Additionally, it has potential use as an emulsifier and surfactant in cosmetic and personal care products.
|
-
-
- HY-N2064
-
|
|
mAChR
|
Neurological Disease
|
|
Racanisodamine is one of the racemic isomers of anisodamine, resembles anisodamine in pharmacological effect. Racanisodamine is a non-selective muscarinic antagonist, used as a component of eye drops for myopic control .
|
-
-
- HY-Y1315
-
|
|
Biochemical Assay Reagents
|
Endocrinology
|
|
DL-Tartaric acid is an orally active and non-racemic mixture of L- and D-tartaric acid with antioxidant activity. 14C-labeled DL-Tartaric acid is nephrotoxic .
|
-
-
- HY-104065A
-
|
(Rac)-SHR-1258
|
Drug Isomer
|
Cancer
|
|
(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemic form of Pyrotinib (HY-104065). Pyrotinib is a potent and selective dual EGFR/HER2 receptor inhibitor.
|
-
-
- HY-115441
-
|
(Rac)-NND 502
|
Antibiotic
Fungal
|
Infection
|
|
(Rac)-Luliconazole ((Rac)-NND 502) is the racemic isomer of Luliconazole (HY-14283). Luliconazole is a topical antifungal imidazole antibiotic with broad-spectrum and potent antifungal activity .
|
-
-
- HY-113904S
-
|
|
Reverse Transcriptase
HIV
HBV
|
Infection
|
|
(Rac)-Tenofovir-d6 is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
|
-
-
- HY-I0635
-
|
(Rac)-CC-10004
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
(Rac)-Apremilast ((Rac)-CC-10004) is the racemic mixture of Apremilast. (Rac)-Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis .
|
-
-
- HY-W010143
-
|
(Rac)-Norcotinine
|
Drug Metabolite
|
Cardiovascular Disease
|
|
(R,S)-Norcotinine ((Rac)-Norcotinine) is the racemic mixture of Norcotinine. (R,S)-Norcotinine is a biomarker of secondhand smoke exposure and is associated with the toxic mechanisms of secondhand smoke on cardiovascular development .
|
-
- HY-B0203BS1
-
-
- HY-145605
-
|
HSG4112
|
Reactive Oxygen Species
Bacterial
PPAR
|
Metabolic Disease
|
|
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent . Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability .
|
-
- HY-130310B
-
|
11-hydroxy-12,14-Eicosadienoic acid
|
COX
|
Metabolic Disease
|
|
(±)11-HEDE is a racemic mixture of the monohydroxy fatty acids 11(S)-HEDE and 11(R)-HEDE. 11-HEDE is formed from eicosadienoic acid by cyclooxygenase (COX) and in macrophages.
|
-
- HY-W752055
-
-
- HY-B0102C
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
(R)-Fluoxetine hydrochloride, an antidepressant, is serotonin reuptake inhibitor (SSRI). (R)-Fluoxetine hydrochloride has modest affinity at the 5-HT2A and 5-HT2C receptors .
|
-
- HY-B0102B
-
-
- HY-19489S1
-
-
- HY-Z0275
-
|
|
Biochemical Assay Reagents
|
Others
|
|
HOAT is a commonly used peptide bond forming agent that may become an impurity in drug synthesis, but is not mutagenic. HOAT can be used for peptide fragment polycondensation and can also inhibit the racemization of peptide polycondensation .
|
-
- HY-113884A
-
|
(±)-13-HODE
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. It is the principle hydroxylated fatty acid in human psoriatic skin scales, with a mean concentration of 17 ng/mg.
|
-
- HY-76251S1
-
|
|
COX
|
Inflammation/Immunology
Cancer
|
|
(rac)-Etodolac-d3 is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)
|
-
- HY-W008914
-
|
|
EGFR
|
Cancer
|
|
(E/Z)-CP-724714 is a racemic compound of (E)-CP-724714 and (Z)-CP-724714 isomers. CP-724714 is a potent and selective orally active ErbB2 (HER2) inhibitor .
|
-
- HY-18733R
-
|
(R)-(+)-α-Lipoic acid(Standard); R-(+)-Thioctic acid (Standard)
|
Mitochondrial Metabolism
Endogenous Metabolite
Reactive Oxygen Species
|
Inflammation/Immunology
Cancer
|
|
Lipoic acid (Standard) is the analytical standard of Lipoic acid. This product is intended for research and analytical applications. Lipoic acid ((R)-(+)-α-Lipoic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. (R)-(+)-α-Lipoic acid is more effective than racemic Lipoic acid.
|
-
- HY-112438A
-
|
|
Deubiquitinase
|
Cancer
|
|
rac-MF-094 is the racemic mixture of MF-094 (HY-112438). MF-094 is a potent and selective USP30 inhibitor with an IC50 of 120 nM. MF-094 increases protein ubiquitination and accelerates mitophagy .
|
-
- HY-W391940
-
|
|
Fungal
Antibiotic
|
Infection
|
|
(Rac)-Amorolfine hydrochloride is the racemic form of Amorolfine hydrochloride. Amorolfine (Ro 14-4767/002) hydrochloride (HY-B0238) is an effective antifungal agent. Amorolfine hydrochloride inhibits the biosynthesis of ergosterol and has research potential for treating onychomycosis caused by Neoscytalidium dimidiatum .
|
-
- HY-Y1315R
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DL-Tartaric acid (Standard) is the analytical standard of DL-Tartaric acid. This product is intended for research and analytical applications. DL-Tartaric acid is a non-racemic mixture of L- and D-tartaric acid with antioxidant activity. 14C-labeled DL-Tartaric acid is nephrotoxic .
|
-
- HY-B2236S
-
|
(±)-2,6-Diaminocaproic acid-d4 dihydrochloride
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
DL-Lysine-4,4,5,5-d4 (dihydrochloride) is the deuterium labeled DL-Lysine. DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins .
|
-
- HY-100841
-
|
3HPG
|
mGluR
|
Neurological Disease
|
|
(Rac)-3-Hydroxyphenylglycine (3HPG) is a racemic mixture of (S)-3-hydroxyphenylglycine and (R)-3-hydroxyphenylglycine. (S)-3-Hydroxyphenylglycine is a potent and selective mGluR1 agonist .
|
-
- HY-15997C
-
|
(±)-Trans-(1R,2R)-U-50488 hydrate hydrochloride
|
Opioid Receptor
|
Neurological Disease
|
|
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrate hydrochloride is a selective κ opioid receptor (KOR) agonist .
|
-
- HY-15997B
-
|
(±)-Trans-(1R,2R)-U-50488 hydrochloride
|
Opioid Receptor
|
Neurological Disease
|
|
(±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrochloride is a selective κ opioid receptor (KOR) agonist .
|
-
- HY-B0259S
-
|
|
Isotope-Labeled Compounds
Potassium Channel
|
Cardiovascular Disease
|
|
(rac)-Indapamide-d3 is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
|
-
- HY-12011A
-
|
|
Bcl-2 Family
|
|
|
(Rac)-HA14-1 is the racemic form of HA14-1 (HY-12011). HA14-1 is a Bcl-2/Bcl-xL antagonist with an IC50 of approximately 9 μM against Bcl-2 .
|
-
- HY-18733S
-
-
- HY-121987A
-
|
|
Lipoxygenase
|
Inflammation/Immunology
|
|
(±)15-HEDE is a racemic mixture of the monohydroxy fatty acids 15(R)-HEDE and 15(S)-HEDE. 15-HEDE is formed from eicosadienoic acid in macrophages. It inhibits 5-lipoxygenase (5-LO; IC50=35 μM).
|
-
- HY-B0105BS
-
|
(-)-Ketoconazol-d3; (-)-R 41400-d3
|
Fungal
|
Infection
Inflammation/Immunology
|
|
(-)-Ketoconazole-d3 is deuterium labeled (-)-Ketoconazole. (-)-Ketoconazole ((-)-R 41400) is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole).
|
-
- HY-B2236S3
-
|
(±)-2,6-Diaminocaproic acid-15N2 hydrochloride
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
DL-Lysine- 15N2 hydrochloride ((±)-2,6-Diaminocaproic acid- 15N2 hydrochloride) is 15N labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.
|
-
- HY-119961
-
|
Dexivacaine; (S)-Mepivacaine
|
Sodium Channel
|
Cardiovascular Disease
|
|
(+)-Mepivacaine is a racemic isomer of Mepivacaine (HY-B0517), which has analgesic and vasoconstrictive activity. Mepivacaine is an amide type agent that temporarily causes local loss of consciousness. Mepivacaine binds to specific voltage-gated sodium channels on neuronal cell membranes, inhibiting sodium influx and membrane depolarization .
|
-
- HY-N0454
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
DL-Arginine is the racemic compound of L-Arginine (HY-N0455) and D-Arginine (HY-W016781). Arginine is an essential amino acid that requires additional supplementation in traumatic or diseased conditions. Arginine is involved in T cell activation, proliferation, and differentiation, and affects the function of immune cells .
|
-
- HY-B0267C
-
|
Aroxybutynin
|
mAChR
|
Neurological Disease
|
|
(R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction .
|
-
- HY-15338A
-
|
|
CDK
|
Cancer
|
|
(E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
|
-
- HY-B2236S1
-
|
(±)-2,6-Diaminocaproic acid-13C6 hydrochloride
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
DL-Lysine- 13C6 hydrochloride ((±)-2,6-Diaminocaproic acid- 13C6 hydrochloride) is 13C-labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.
|
-
- HY-173388
-
|
|
Toll-like Receptor (TLR)
JNK
NF-κB
NO Synthase
COX
|
Inflammation/Immunology
|
|
TLR4-IN-2 (Compound Racemic-11k) is inhibitors of TLR4, JNK, and NF-κB. TLR4-IN-2 inhibits NO production in LPS-stimulated RAW264.7 cells with an IC50 value of 23.2 µM. TLR4-IN-2 exerts anti-inflammatory activity by inhibiting TLR4 expression, reducing JNK phosphorylation, thereby suppressing the activation of NF-κB, blocking the transcription of inflammation-related genes, reducing the expression of iNOS and COX-2, and decreasing the production of inflammatory mediators such as NO, PGE 2, and TNF-α. TLR4-IN-2 is promising for research of inflammatory diseases, such as rheumatoid arthritis and various inflammatory disorders .
|
-
- HY-126108
-
|
|
Others
|
Metabolic Disease
|
|
(±)8-HEPE is produced by non-enzymatic oxidation of EPA. It contains equal amounts of (±)8-HEPE and 8(R)-HEPE. The ability of (±)8-HEPE to induce hatching of E. modestus and B. balanoides eggs is probably due to the presence of the 8(R) isomer within the racemic mixture.
|
-
- HY-138794A
-
|
|
Deubiquitinase
|
Cancer
|
|
(Rac)-XL177A is the racemic isomer of XL177A (HY-138794). XL177A is a highly potent and selective irreversible USP7 inhibitor with an IC50 of 0.34 nM. XL177A elicits cancer cell-killing effects through a p53-dependent mechanism .
|
-
- HY-B0105B
-
|
(-)-Ketoconazol; (-)-R 41400
|
Fungal
Cytochrome P450
|
Infection
Inflammation/Immunology
|
|
(-)-Ketoconazole ((-)-R 41400) is one of the enantiomers of ketoconazole (HY-B0105). Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole). Ketoconazole is an antifungal agent and a cytochrome P450 inhibitor.
|
-
- HY-12364C
-
|
(+)-C75
|
Mitochondrial Metabolism
|
Others
|
|
(+)-trans-C75 ((+)-C75) is an enantiomer of C75 (HY-12364) (a fatty acid synthase inhibitor). (+)-trans-C75 is less potent than the racemic mixture or the (-) enantiomer in enhancing the cancer-killing ability of ionizing radiation. (+)-trans-C75 inhibits CPT1 and is an anorectic agent .
|
-
- HY-107459
-
|
(E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42
|
EGFR
STAT
JAK
|
Cancer
|
|
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
|
-
- HY-14258
-
|
(S)-Citalopram; (S)-(+)-Citalopram
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .
|
-
- HY-P2834
-
|
PGA
|
Biochemical Assay Reagents
|
Infection
Cancer
|
|
Penicillin amidase (EC 3.5.1.11) (Penicillin acylase) is an enzyme that cleaves the acyl side chains of penicillins. Penicillin amidase can be used for the production of 6-aminopenicillanic acid. Penicillin amidase can also be used in the resolution of racemic mixtures, peptide synthesis, and synthesis of semi-synthetic β-lactam antibiotics .
|
-
- HY-14258A
-
|
(S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate
|
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-112149A
-
|
|
Epigenetic Reader Domain
|
Inflammation/Immunology
Cancer
|
|
(E/Z)-ZL0420 is a racemic compound of (Z)-ZL0420 and (E)-ZL0420 isomers. (E)-ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2 .
|
-
- HY-137258
-
|
|
Cytochrome P450
|
Metabolic Disease
|
|
(±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with Ki values of 0.25 and 5.3 μM for CYP2C19, respectively .
|
-
- HY-B2236S2
-
|
(±)-2,6-Diaminocaproic acid-13C6,15N2 hydrochloride
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
DL-Lysine- 13C6, 15N2 hydrochloride ((±)-2,6-Diaminocaproic acid- 13C6, 15N2 hydrochloride) is 13C and 15N-labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.
|
-
- HY-B0827A
-
|
(R)-MTI-446
|
nAChR
Parasite
|
Infection
|
|
(R)-Dinotefuran ((R)-MTI-446), a neonicotinoid pesticide, exhibits comparative insecticidal activities (1.7-2.4 times) to typical sucking pests Aphis gossypii and Apolygus lucorum compared to racemic mixtures by inhibiting nicotinic acetylcholine receptors. (R)-Dinotefuran has a good efficacy in controlling target pests while minimizing hazard to honeybees .
|
-
- HY-131904
-
POMHEX
3 Publications Verification
|
Enolase
Apoptosis
|
Metabolic Disease
Cancer
|
|
POMHEX, a racemic mixture and a cell-permeable pivaloyloxymethyl (POM) proagent of HEX, is a potent, ENO2-specific inhibitor of enolase. POMHEX exhibits low-nanomolar potency against ENO1-deleted cells in vitro and is capable of eradicating ENO1-deleted xenografted tumours in vivo. POMHEX is a potent glycolysis inhibitor .
|
-
- HY-111226A
-
|
|
Estrogen Receptor/ERR
Reactive Oxygen Species
|
Cardiovascular Disease
Cancer
|
|
(E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers. GSK5182 is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with an IC50 of 79 nM . GSK5182 also induces reactive oxyen species (ROS) generation in hepatocellular carcinoma .
|
-
- HY-17494S
-
|
(Rac)-L-714,465-d5 maleate; (Rac)-MK 950-d5
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
rac Timolol-d5 (maleate) is a labelled racemic (S)-Timolol maleate. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction .
|
-
- HY-16950AR
-
|
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Cancer
|
|
(E/Z)-4-Hydroxytamoxifen (Standard) is the analytical standard of (E/Z)-4-Hydroxytamoxifen. This product is intended for research and analytical applications. (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is an estrogen receptor modulator.
|
-
- HY-100573A
-
|
|
Mixed Lineage Kinase
|
Cancer
|
|
(E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis .
|
-
- HY-112163A
-
|
rel-eFT226
|
Eukaryotic Initiation Factor (eIF)
SARS-CoV
Apoptosis
|
Infection
Cancer
|
|
rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex .
|
-
- HY-B0267CS
-
|
Aroxybutynin-d10
|
Isotope-Labeled Compounds
mAChR
|
Neurological Disease
|
|
(R)-Oxybutynin-d10 (Aroxybutynin-d10) is deuterium labeled (R)-Oxybutynin. (R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction .
|
-
- HY-112847B
-
|
(E/Z)-Sulfo-N-succinimidyl oleate sodium
|
Mitophagy
|
Inflammation/Immunology
|
|
(E/Z)-Sulfosuccinimidyl oleate sodium is a racemic compound of (Z)-Sulfosuccinimidyl oleate sodium and (Z)-Sulfosuccinimidyl oleate sodium isomers. Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of mitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds the CD36 receptor on the surface of microglia. Sulfosuccinimidyl oleate sodium has anti-inflammatory effect .
|
-
- HY-14258AS
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram-d6 (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-Z7721
-
|
(Rac)-TRK-100; (Rac)-ML 1129 sodium
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
(Rac)-Beraprost ((Rac)-ML 1129) sodium is a racemic isomer of Beraprost sodium (HY-13569A). Beraprost sodium is an orally active prostacyclin analog that inhibits the release of Ca 2+ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost sodium has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .
|
-
- HY-14258AS1
-
|
(S)-Citalopram-d4 oxalate; (S)-(+)-Citalopram-d4 oxalate
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram-d4 (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-14258AR
-
|
(S)-Citalopram (oxalate) (Standard); (S)-(+)-Citalopram (oxalate) (Standard)
|
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Escitalopram (oxalate) (Standard) is the analytical standard of Escitalopram (oxalate). This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-19202
-
|
rac-EMA401; rac-PD-126055; EMA400
|
Angiotensin Receptor
|
Neurological Disease
|
|
rac-Olodanrigan (rac-EMA401; EMA400) is a racemic mixture of the S-enantiomer (EMA401; HY-13106) and R-enantiomer (EMA402). rac-Olodanrigan is a potent and selective AT2 receptor antagonist with IC50s of 75.2 nM and 2918 nM for AT2R and AT1R, respectively. rac-Olodanrigan evokes dose-dependent relief of mechanical allodynia in the ipsilateral hind paws of rats with a chronic constriction injury (CCI) of the sciatic nerve .
|
-
- HY-17368S1
-
|
(Rac)-ENA 713-d6 free base; (Rac)-SDZ-ENA 713-d6 free base
|
Isotope-Labeled Compounds
Cholinesterase (ChE)
|
Neurological Disease
|
|
(Rac)-Rivastigmine-d6 is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
|
-
- HY-126144A
-
|
|
GSK-3
|
Metabolic Disease
|
|
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM .
|
-
- HY-W013411
-
|
(E/Z)-UIC-1005
|
Raf
|
Cancer
|
|
(E/Z)-Locostatin ((E/Z)-UIC-1005) is a racemic of Locostatin. Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice .
|
-
- HY-10572BS
-
|
|
Isotope-Labeled Compounds
Reverse Transcriptase
HIV
Autophagy
|
Infection
Cancer
|
|
(Rac)-Efavirenz-d4 is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture . (Rac)-Efavirenz-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N0106
-
|
(Rac)-Danshensu sodium; (Rac)-Tanshinol sodium
|
Keap1-Nrf2
NF-κB
Mitochondrial Metabolism
Apoptosis
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
|
(Rac)-Salvianic acid A sodium is the racemic form of Salvianic acid A (HY-N1913). Salvianic acid A is an orally active phenolic compound that induces Nrf2/HO-1 activation and inhibits the NF-κB pathway, and it also activates the mitochondrial antioxidant defense system (Mitochondrial Metabolism). Salvianic acid A exhibits anti-inflammatory, antioxidant, and anti-apoptotic properties (Apoptosis), demonstrating potential for research into inflammation and cardiovascular diseases .
|
-
- HY-113764
-
|
(Rac)-C4-HSL
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
N-Butanoyl-DL-homoserine lactone ((Rac)-C4-HSL) is a racemic mixture of N-Butanoyl-D-homoserine lactone and N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa .
|
-
- HY-N2362
-
|
DL-2-Aminopropionic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-108539A
-
|
|
Ras
|
Metabolic Disease
|
|
(R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (Epac1), with an IC50 of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC50, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4 .
|
-
- HY-116790B
-
|
(Rac)-Penbutolol; (±)-Isopenbutolol
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(±)-Penbutolol ((Rac)-Penbutolol) is the racemic mixture of Penbutolol. (±)-Penbutolol is an orally active β-adrenergic receptor antagonist. (±)-Penbutolol antagonizes exercise-induced tachycardia, reduces the increase in peak expiratory flow rate (PEFR) caused by exercise, and decreases resting plasma renin activity (PRA). (±)-Penbutolol reaches peak plasma concentration 1 hour after oral administration, with a half-life of 4.5 hours, and is converted into an active metabolite in the body. (±)-Penbutolol can be used in cardiovascular-related disease research .
|
-
- HY-W012908
-
|
|
Biochemical Assay Reagents
|
Infection
Cancer
|
|
DL-Proline is a racemic mixture of D-Proline and L-Prolin. DL-Proline is a cyclic imino acid with a five-membered ring structure. DL-Proline is a key structural unit in peptide synthesis. DL-Proline can stabilize the β-turn conformation and affect the secondary structure of the peptide. DL-Proline has biological activities such as regulating peptide conformation and enhancing the stability of cyclic peptides. DL-Proline can be used to study diseases related to peptide structure and function, such as cancer and bacterial infection .
|
-
- HY-W010712S1
-
|
|
Isotope-Labeled Compounds
Amino Acid Derivatives
|
Others
|
|
Fmoc-His(Trt)-OH- 15N3 is the 15N labeled Fmoc-His(Trt)-OH (HY-W010712). Fmoc-His (Trt)-OH is a histidine derivative. Fmoc-His(Trt)-OH has trityl (Trt) group to protect the side-chain of His. Fmoc-His(Trt)-OH has Fmoc group to protect -αNH2. Fmoc-His(Trt)-OH can be used for solid phase synthesis of peptides, providing protection against racemization and by-product formation .
|
-
- HY-N0106R
-
|
|
Keap1-Nrf2
NF-κB
Mitochondrial Metabolism
Apoptosis
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
|
(Rac)-Salvianic acid A (sodium) (Standard) is the analytical standard of (Rac)-Salvianic acid A (sodium). This product is intended for research and analytical applications. (Rac)-Salvianic acid A sodium is the racemic form of Salvianic acid A (HY-N1913). Salvianic acid A is an orally active phenolic compound that induces Nrf2/HO-1 activation and inhibits the NF-κB pathway, and it also activates the mitochondrial antioxidant defense system (Mitochondrial Metabolism). Salvianic acid A exhibits anti-inflammatory, antioxidant, and anti-apoptotic properties (Apoptosis), demonstrating potential for research into inflammation and cardiovascular diseases .
|
-
- HY-N2362S2
-
|
DL-2-Aminopropionic acid-d3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine-d3 is the deuterium labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-N2362S5
-
|
DL-2-Aminopropionic acid-15N
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine- 15N is the 15N labeled DL-Alanine . DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-N2362S
-
|
DL-2-Aminopropionic acid-13C-1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine- 13C-1 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-103019A
-
|
(±)-BAY-1251152; (±)-VIP152
|
CDK
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC + lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .
|
-
- HY-N2362S1
-
|
DL-2-Aminopropionic acid-13C-3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine- 13C-3 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-137390A
-
|
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
Metabolic Disease
|
|
(3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
|
-
- HY-16950A
-
|
Afimoxifene; 4-OHT
|
Estrogen Receptor/ERR
Adhesion G Protein-coupled Receptors (AGPCRs)
Drug Metabolite
|
Metabolic Disease
Cancer
|
|
(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective estrogen receptor modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity .
|
-
- HY-N2362S8
-
|
DL-2-Aminopropionic acid-d7
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
DL-Alanine-d7 (DL-2-Aminopropionic acid-d7) is deuterium labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-15746S1
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
(rac)-Dobutamine-d6 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion .
|
-
- HY-15997
-
|
(-)-Trans-(1S,2S)-U-50488 hydrochloride
|
Opioid Receptor
|
Infection
Cancer
|
|
(-)-U-50488 hydrochloride ((-)-Trans-(1S,2S)-U-50488 hydrochloride) is a selective kappa-opioid receptor (KOR) agonist (b>Kd=2.2 nM) over μ-opioid receptor (MOR) (b>Kd=430 nM). (-)-U-50488 hydrochloride is a more active enantiomer than (+)?trans-(1R,2R) U-50488 (HY-15997A)?or the (±)?trans-racemic mixture U-50488 (HY-15997B). (-)-U-50488 hydrochloride has a potent and sustained anti-HIV effect in fected blood monocyte-derived macrophages (MDM) .
|
-
- HY-N2362S9
-
|
DL-2-Aminopropionic acid-13C2,15N2
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine- 13C2, 15N (DL-2-Aminopropionic acid- 13C2, 15N) is 13C and 15N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-15746S
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
(rac)-Dobutamine-d4 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion .
|
-
- HY-132184
-
|
5,6-EET; (±)5,6-EpETrE
|
Adrenergic Receptor
Calcium Channel
|
Endocrinology
|
|
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
|
-
- HY-118156
-
|
|
Others
|
Others
|
|
L-699333 is a 5-lipoxygenase (5-LO) inhibitor belonging to the thieno[2,3,4-cd]indole class. This compound has a 2-ethoxybutyric acid side chain and is a potent inhibitor of the biosynthesis of 5-HPETE and LTB4 produced from human 5-LO, with ICm values of 22 nM, 7 nM, and 3.8 pM for human neutrophils and whole blood, respectively. L-699333 has shown anti-inflammatory and antiasthmatic effects in a variety of animal models, including rat pleurisy models, antigen-induced wheezing models, and awake macaque and sheep asthma models. Its inhibition of 5-LO is highly selective, with higher ICm values or stronger competitive inhibition in FLAP binding assays compared to inhibition of human 15-LO, porcine 12-LO, and ram epididymal cyclooxygenase. The racemic enantiomer 14g of L-699333 is the most potent enantiomer to date, with inhibitory effects similar to those of the known MK-0591, which has been shown in clinical trials to inhibit the biochemical effects of LTB4 biosynthesis in vitro and LTE4 excretion in urine.
|
-
- HY-132184S
-
|
5,6-EET-d11; (±)5,6-EpETrE-d11
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Endocrinology
|
|
5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W127386
-
|
3-Dodecyloxypropane-1,2-diol
|
Drug Delivery
|
|
1-O-Dodecyl-rac-glycerol is a class of organic compounds belonging to the class of racemic glycerol derivatives. It consists of a dodecyl chain attached to the sn-1 position of the racemic glycerol molecule. 1-O-Dodecyl-rac-glycerol has various applications in the pharmaceutical industry, especially as an intermediate in the synthesis of lipid drug delivery systems and membranes. Additionally, it has potential use as an emulsifier and surfactant in cosmetic and personal care products.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W010712
-
|
|
Amino Acid Derivatives
|
Others
|
|
Fmoc-His (Trt)-OH is a histidine derivative. Fmoc-His(Trt)-OH has trityl (Trt) group to protect the side-chain of His. Fmoc-His(Trt)-OH has Fmoc group to protect -αNH2. Fmoc-His(Trt)-OH can be used for solid phase synthesis of peptides, providing protection against racemization and by-product formation .
|
-
- HY-W012908
-
|
|
Biochemical Assay Reagents
|
Infection
Cancer
|
|
DL-Proline is a racemic mixture of D-Proline and L-Prolin. DL-Proline is a cyclic imino acid with a five-membered ring structure. DL-Proline is a key structural unit in peptide synthesis. DL-Proline can stabilize the β-turn conformation and affect the secondary structure of the peptide. DL-Proline has biological activities such as regulating peptide conformation and enhancing the stability of cyclic peptides. DL-Proline can be used to study diseases related to peptide structure and function, such as cancer and bacterial infection .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-14605BS
-
|
|
|
Rasagiline- 13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor . Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-113904S
-
|
|
|
(Rac)-Tenofovir-d6 is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
|
-
-
- HY-B2236S
-
|
|
|
DL-Lysine-4,4,5,5-d4 (dihydrochloride) is the deuterium labeled DL-Lysine. DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins .
|
-
-
- HY-107370AS
-
|
|
|
(Rac)-Atomoxetine-d7 (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .
|
-
-
- HY-B0203BS2
-
|
|
|
(Rac)-Nebivolol-d2, 15N is 15N and deuterated labeled (Rac)-Nebivolol (HY-B0203B). (Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity .
|
-
-
- HY-B0203BS1
-
|
|
|
(rac)-Nebivolol-d4 is a labelled racemic Nebivolol. Nebivolol selectively inhibits β1- adrenergic receptor with IC50 of 0.8 nM[1][2].
|
-
-
- HY-W752055
-
|
|
|
(Rac)-Nebivolol-d4 hydrochloride is a labelled racemic Nebivolol. Nebivolol selectively inhibits β1-adrenergic receptor with an IC50 of 0.8 nM .
|
-
-
- HY-19489S1
-
|
|
|
(Rac)-Levomepromazine-d3 (hydrochloride) is a labelled racemic Methotrimeprazine, which is a phenothiazine which has antagonist actions at multiple neurotransmitter receptor sites, including dopaminergic, cholinergic, serotonin and histamine receptors .
|
-
-
- HY-76251S1
-
|
|
|
(rac)-Etodolac-d3 is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)
|
-
-
- HY-B0259S
-
|
|
|
(rac)-Indapamide-d3 is a labelled racemic Indapamide. Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
|
-
-
- HY-18733S
-
|
|
|
Lipoic acid-d4 ((R)-(+)-α-Lipoic acid-d4) is deuterium labeled Lipoic acid. Lipoic acid ((R)-(+)-α-Lipoic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. (R)-(+)-α-Lipoic acid is more effective than racemic Lipoic acid .
|
-
-
- HY-B0105BS
-
|
|
|
(-)-Ketoconazole-d3 is deuterium labeled (-)-Ketoconazole. (-)-Ketoconazole ((-)-R 41400) is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole).
|
-
-
- HY-B2236S3
-
|
|
|
DL-Lysine- 15N2 hydrochloride ((±)-2,6-Diaminocaproic acid- 15N2 hydrochloride) is 15N labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.
|
-
-
- HY-B2236S1
-
|
|
|
DL-Lysine- 13C6 hydrochloride ((±)-2,6-Diaminocaproic acid- 13C6 hydrochloride) is 13C-labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.
|
-
-
- HY-B2236S2
-
|
|
|
DL-Lysine- 13C6, 15N2 hydrochloride ((±)-2,6-Diaminocaproic acid- 13C6, 15N2 hydrochloride) is 13C and 15N-labeled DL-Lysine (HY-B2236). DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins.
|
-
-
- HY-17494S
-
|
|
|
rac Timolol-d5 (maleate) is a labelled racemic (S)-Timolol maleate. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction .
|
-
-
- HY-B0267CS
-
|
|
|
(R)-Oxybutynin-d10 (Aroxybutynin-d10) is deuterium labeled (R)-Oxybutynin. (R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction .
|
-
-
- HY-14258AS
-
|
|
|
Escitalopram-d6 (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
-
- HY-14258AS1
-
|
|
|
Escitalopram-d4 (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
-
- HY-17368S1
-
|
|
|
(Rac)-Rivastigmine-d6 is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .
|
-
-
- HY-10572BS
-
|
|
|
(Rac)-Efavirenz-d4 is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture . (Rac)-Efavirenz-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-W010712S1
-
|
|
|
Fmoc-His(Trt)-OH- 15N3 is the 15N labeled Fmoc-His(Trt)-OH (HY-W010712). Fmoc-His (Trt)-OH is a histidine derivative. Fmoc-His(Trt)-OH has trityl (Trt) group to protect the side-chain of His. Fmoc-His(Trt)-OH has Fmoc group to protect -αNH2. Fmoc-His(Trt)-OH can be used for solid phase synthesis of peptides, providing protection against racemization and by-product formation .
|
-
-
- HY-N2362S2
-
|
|
|
DL-Alanine-d3 is the deuterium labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-N2362S5
-
|
|
|
DL-Alanine- 15N is the 15N labeled DL-Alanine . DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-N2362S
-
|
|
|
DL-Alanine- 13C-1 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-N2362S1
-
|
|
|
DL-Alanine- 13C-3 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-N2362S8
-
|
|
|
DL-Alanine-d7 (DL-2-Aminopropionic acid-d7) is deuterium labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-15746S1
-
|
|
|
(rac)-Dobutamine-d6 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion .
|
-
-
- HY-N2362S9
-
|
|
|
DL-Alanine- 13C2, 15N (DL-2-Aminopropionic acid- 13C2, 15N) is 13C and 15N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-15746S
-
|
|
|
(rac)-Dobutamine-d4 (hydrochloride) is a labelled racemic Dobutamine hydrochloride. Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion .
|
-
-
- HY-132184S
-
|
|
|
5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-14605BS
-
|
AGN1135-13C3; TVP1012-13C3 Racemic
|
|
Alkynes
|
|
Rasagiline- 13C3 (mesylate racemic) is a 13C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor . Rasagiline-13C3 (mesylate racemic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
